Immunohistochemical evidence for sclerostin during cementogenesis in mice

Annals of Anatomy

Volumn 194, Issue 5, 2012, Pages 415-421

  Lehnen, Sandra D M ^a   Götz, Werner ^b   Baxmann, Martin ^b,c,d   Jäger, Andreas ^e  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d University Dental School ^*  (Germany)

^e Department of Orthodontics   (Germany)

Author keywords

Cementocytes; Cementogenesis; Immunohistochemistry; Sclerostin; SOST gene

Indexed keywords

CALVASCULIN ANTIBODY; SCLEROSTIN; TRANSCRIPTION FACTOR RUNX2 ANTIBODY; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ALVEOLAR BONE; ANIMAL TISSUE; CELL MATURATION; CEMENTUM; CONTROLLED STUDY; DEVELOPMENTAL STAGE; FIBROBLAST; GENE PRODUCT; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MANDIBLE; MAXILLA; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; PERIODONTAL LIGAMENT; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SHORT SURVEY; SOST GENE; TISSUE DISTRIBUTION; TOOTH DEVELOPMENT;

MUS;

EID: 84865728578     PISSN: 09409602     EISSN: 16180402     Source Type: Journal    
DOI: 10.1016/j.aanat.2012.02.014     Document Type: Short Survey

References (43)

1. Armitage G.C. Cementum. Orban's Oral Histology and Embryology 1980, 180-203. Mosby, London. S.N. Bhaskar (Ed.).
2. Ayasaka N., Kondo T., Goto T., et al. Differences in the transport systems between cementocytes and osteocytes in rats using microperoxidase as a tracer. Arch. Oral. Biol. 1992, 37:363-369.
3. Balemans W., Ebeling M., Patel N., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 2001, 10:537-543.
4. Bonewald L.B. The amazing osteocyte. J. Bone Miner. Res. 2011, 26:229-238.
5. Bosshardt D.D. Are cementoblasts a subpopulation of osteoblasts or a unique phenotype?. J. Dent. Res. 2005, 84:390-406.
6. Bosshardt D.D., Schroeder H.E. Initial formation of cellular intrinsic fiber cementum in developing human teeth. A light- and electron-microscopic study. Cell Tissue Res. 1992, 267:321-335.
7. Bosshardt D.D., Schroeder H.E. Cementogenesis reviewed: a comparison between human premolars and rodent molars. Anat Rec. 1996, 245:267-292.
8. Canalis E., Economides A.N., Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr. Rev. 2003, 24:218-235.
9. Cohn S.A. Development of the molar teeth in the albino mouse. Am. J. Anat. 1957, 101:295-319.
10. D'Errico J.A., MacNeil R.L., Takata T., et al. Expression of bone associated markers by tooth root lining cells, in situ and in vitro. Bone 1997, 20:117-126.
11. D'Errico J.A., Berry J.E., Ouyang H., et al. Employing a transgenic animal model to obtain cementoblasts in vitro. J. Periodontol. 2000, 71:63-72.
12. Diekwisch T.G. The developmental biology of cementum. Int. J. Dev. Biol. 2001, 45:695-706.
13. Hartmann C. A Wnt canon orchestrating osteoblastogenesis. Trends Cell Biol. 2006, 16:151-158.
14. Foster B.L., Popowics T.E., Fong H.K., et al. Advances in defining regulators of cementum development and periodontal regeneration. Curr. Top. Dev. Biol. 2007, 78:47-126.
15. Henry J.L., Weinmann J.P. The pattern of resorption and repair of human cementum. J. Am. Dent. Assoc. 1951, 42:270-290.
16. Frank R.M., Steuer P. Ultrastructural study of the cellular cementum in rats. J. Biol. Buccale 1977, 5:121-135.
17. Li X., Zhang Y., Kang H., et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 2005, 280:19883-19887.
18. Jäger A., Götz W., Lossdörfer S., Rath-Deschner B. Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro. J. Periodontal. Res. 2009, 45:246-254.
19. Kagayama M., Sasano Y., Mizoguchi I., et al. Confocal microscopy of cementocytes and their lacunae and canaliculi in rat molars. Anat. Embryol. 1997, 195:491-496.
20. Kitagawa M., Tahara H., Kitagawa S., et al. Characterization of established cementoblast-like cell lines from human cementum-lining cells in vitro and in vivo. Bone 2006, 39:1035-1042.
21. Kneissel M. The promise of sclerostin inhibition for the treatment of osteoporosis. IBMS BoneKEy 2009, 6:259-264.
22. Kolpakova E., Olsen B.R. Wnt/beta-catenin - a canonical tale of cell-fate choice in the vertebrate skeleton. Dev. Cell 2005, 8:626-627.
23. Krishnan V., Bryant H.U., MacDougald O.A. Regulation of bone mass by Wnt signaling. J. Clin. Invest. 2006, 116:1202-1209.
24. Leonardi R., Loreto C., Caltabiano R., et al. Immunolocalization of CD44s in human teeth. Acta Histochem. 2006, 108:425-429.
25. Loots G.G., Kneissel M., Keller H., et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005, 15:928-935.
26. Moester M.J., Papapoulos S.E., Löwik C.W., van Bezooijen R.L. Sclerostin: current knowledge and future perspectives. Calcif. Tissue Int. 2010, 87:99-107.
27. Nemoto E., Koshikawa Y., Kanaya S., et al. Wnt signaling inhibits cementoblast differentiation and promotes proliferation. Bone 2009, 44:805-812.
28. Ominsky M.S., Li C., Li X., Tan H.L., Lee E., et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J. Bone Miner. Res. 2011, 26:1012-1021.
29. Ott S.M. Sclerostin and Wnt signaling - the pathway to bone strength. J. Clin. Endocrinol. Metab. 2005, 90:6741-6743.
30. Poole K.E., van Bezooijen R.L., Loveridge N., Hamersma H., Papapoulos S.E., Lowik C.W., Reeve J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005, 19:1842-1844.
31. Schroeder H.E. Orale Strukturbiologie 2000, Thieme, Stuttgart-New York.
32. Rooker S.M., Liu B., Helms J.A. Role of Wnt signaling in the biology of the periodontium. Dev. Dyn. 2010, 239:140-147.
33. Semenov M., Tamai K., He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 2005, 280:26770-26775.
34. Siverman S.L. Sclerostin. J. Osteoporos. 2010, 2010:941419.
35. Slavkin H.C., Bringas P. Epithelial-mesenchyme interactions during odontogenesis. IV. Morphological evidence for direct heterotypic cell-cell contacts. Dev. Biol. 1976, 50:428-442.
36. Tenorio D., Cruchley A., Hughes F.J. Immunocytochemical investigation of the rat cementoblast phenotype. J. Periodontal. Res. 1993, 28:411-419.
37. van Bezooijen R.L., ten Dijke P., Papapoulos S.E., et al. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 2005, 16:319-327.
38. van Bezooijen R.L., Roelen B.A., Visser A., et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 2004, 199:805-814.
39. van Bezooijen R.L., Svensson J.P., Eefting D., et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J. Bone Miner. Res. 2007, 22:19-28.
40. van Bezooijen R.L., Bronckers A.L., Gortzak R.A., et al. Sclerostin in mineralized matrices and van Buchem disease. J. Dent. Res. 2009, 88:569-574.
41. Warmington K., Morony S., Sarosi I., et al. Sclerostin antagonism in adult rodents, via monoclonal antibody mediated blockade, increases bone mineral density and implicates sclerostin as a key regulator of bone mass during adulthood. J. Bone Miner. Res. 2004, 19:S56.
42. Winkler D.G., Sutherland M.K., Geoghegan J.C., et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003, 22:6267-6276.
43. Zhao M., Xiao G., Berry J.E., et al. Bone morphogenetic protein 2 induces dental follicle cells to differentiate toward a cementoblast/osteoblast phenotype. J. Bone Miner. Res. 2002, 17:1441-1451.